[HTML] nih.gov

ALK-positive lung cancer: a moving target

JL Schneider, JJ Lin, AT Shaw - Nature cancer, 2023 - nature.com
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …
被引用次数：50 相关文章 所有 7 个版本
[HTML] nih.gov

Targeting ALK: precision medicine takes on drug resistance

JJ Lin, GJ Riely, AT Shaw - Cancer discovery, 2017 - AACR
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
被引用次数：498 相关文章 所有 5 个版本
[PDF] mdpi.com

Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer

H Isozaki, N Takigawa, K Kiura - Cancers, 2015 - mdpi.com
The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic
lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung …
被引用次数：81 相关文章 所有 15 个版本
[PDF] mdpi.com

Tumor resistance against ALK targeted therapy-where it comes from and where it goes

GG Sharma, I Mota, L Mologni, E Patrucco… - Cancers, 2018 - mdpi.com
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has …
被引用次数：89 相关文章 所有 15 个版本
[HTML] nih.gov

ALK in Lung Cancer: Past, Present, and Future

AT Shaw, JA Engelman - Journal of clinical oncology, 2013 - ascopubs.org
In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements
are present in a small subset of non–small-cell lung cancers. ALK-positive cancers are …
被引用次数：520 相关文章 所有 8 个版本
[PDF] tandfonline.com

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

PL Chia, P Mitchell, A Dobrovic, T John - Clinical epidemiology, 2014 - Taylor & Francis
Improved understanding of molecular drivers of carcinogenesis has led to significant
progress in the management of lung cancer. Patients with non-small-cell lung cancer …
被引用次数：200 相关文章 所有 18 个版本
[HTML] nih.gov

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine

R Katayama, CM Lovly, AT Shaw - Clinical Cancer Research, 2015 - AACR
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as
a component of the fusion protein nucleophosmin (NPM)–ALK in anaplastic large-cell …
被引用次数：275 相关文章 所有 6 个版本
[HTML] nih.gov

Treating ALK-positive lung cancer—early successes and future challenges

DR Camidge, RC Doebele - Nature reviews Clinical oncology, 2012 - nature.com
Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-
small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed …
被引用次数：273 相关文章 所有 9 个版本
[HTML] nih.gov

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner… - Cancer discovery, 2016 - AACR
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …
被引用次数：1119 相关文章 所有 7 个版本
[HTML] nih.gov

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors

JM Heuckmann, M Hölzel, ML Sos, S Heynck… - Clinical Cancer …, 2011 - AACR
Purpose: EML4–ALK fusions define a subset of lung cancers that can be effectively treated
with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is …
被引用次数：231 相关文章 所有 13 个版本